Abstracts tagged "Outcome measures"

Abstract Number: 0092 • ACR Convergence 2022
Characterizing Levels of Specialist Care Received by Patients with Systemic Lupus Erythematosus: Clinical Characteristics, Emergency Care, Hospitalization, and Costs Among Commercially-insured Adults in the United States
Sandra Sze-jung Wu¹, Allison Perry², Helen Varker³, Christine Dube¹ and Gary Bryant⁴, ¹AstraZeneca, Wilmington, DE, ²IBM Watson Health, Cambridge, MA, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Heterogeneous SLE manifestations can delay referral and diagnosis by a rheumatologist (rheum) in as many as 75% of patients (pts) with SLE.1 After diagnosis,…
Abstract Number: 0319 • ACR Convergence 2022
Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy
Daming Shao¹, Alejandra Londoño Jimenez², Maria Auxiliadora Salgado Guerrero³, Anna Broder⁴ and Shudan Wang⁵, ¹Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²McFarland Clinic, Ames, IA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hackensack University Medical Center, Hackensack, NJ, ⁵Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). Approximately 10 to 30% of patients with LN progress…
Abstract Number: 0729 • ACR Convergence 2022
Understanding the Practice and Process of Patient Reported Outcome Measures Collection in North American Pediatric Rheumatology Clinics: A Survey of the Pediatric Rheumatology-Care and Outcomes Improvement Network
Y. Ingrid Goh¹, Esi Morgan², Meghan Ryan³, Beth Gottlieb⁴ and Nancy Pan⁵, ¹Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, ²Seattle Children's Hospital, Seattle, WA, ³University of Minnesota, Vadnais Heights, MN, ⁴Cohen Children's Medical Center, Lake Success, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Patients/proxies (Pts) complete patient reported outcome measures (PROMs) to inform their healthcare team about their health status. PROMs completed by Pts prior to their…
Abstract Number: 1214 • ACR Convergence 2022
In-hospital Outcomes of Autoimmune Diseases Complicated by Interstitial Lung Disease: A National Inpatient Sample Analysis
Sandhya shri Kannayiram¹ and Shilpa Arora², ¹John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Several autoimmune diseases (AD) may be associated with interstitial lung disease (ILD), contributing to increased morbidity and mortality in these patients. We aimed to…
Abstract Number: 1414 • ACR Convergence 2022
2022 Revision of the ACR/EULAR Remission Criteria for Rheumatoid Arthritis
Paul Studenic¹, Daniel Aletaha², Maarten de Wit³, Tanja Stamm⁴, Farideh Alasti⁵, Diane Lacaille⁶, Josef Smolen¹ and David Felson⁷, ¹Medical University of Vienna, Vienna, Austria, ²Medical University Vienna, Wien, Austria, ³Patient research partner, Amsterdam, Netherlands, ⁴Medical University of Vienna, CeMSIIS - Center for Medical Statistics, Informatics, and Intelligent Systems, Section for Outcomes Research, Wien, Austria, ⁵Medical University of Vienna, Department of Internal Medicine 3, Division of Rheumatology, Vienna, Austria, ⁶Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁷Boston University, Boston, MA
Background/Purpose: More than 10 years ago ACR and EULAR endorsed provisional criteria to define remission in RA, both Boolean and index-based. However, the agreement between…
Abstract Number: 1871 • ACR Convergence 2022
Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
Zi Ying Li¹, Siyi Huang², Kevin Xi³, Deepan Dalal⁴ and Anthony Reginato⁵, ¹Roger Williams Medical Center, Providence, RI, ²UCSF Fresno, Fresno, CA, ³Brown University, Providence, ⁴Brown University School of Medicine, Providence, RI, ⁵Brown University, Providence, RI
Background/Purpose: Cardiovascular disease was encountered in 15% of hospital admission from 2016-2017 for patients with idiopathic inflammatory myopathies (IIM) based on the National Inpatient Sample…
Abstract Number: 2109 • ACR Convergence 2022
Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Arthur Kavanaugh¹, Gordon Lam², Lai-shan Tam³, Natalie Shiff⁴, Youngja Lee⁵, Ana-Maria Bravo Perdomo⁶, May Shawi⁷, Elizabeth Hsia⁸, Emmanouil Rampakakis⁹ and Carlos Enrique Toro Gutiérrez¹⁰, ¹University of California San Diego, La Jolla, CA, ²Arthritis and Osteoporosis Consultants of the Carolinas; Clinical Affiliate, Atrium Health and the Wake Forest School of Medicine, Cornelius, NC, ³The Chinese University of Hong Kong, Hong Kong, China, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, USA/ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, Philadelphia, PA, ⁵Immunology Medical Affairs, Janssen Asia Pacific, Yongsan-gu, Seoul, Republic of Korea, ⁶Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Janssen Research and Development, LLC; University of Pennsylvania School of Medicine, Kennett Square, PA, ⁹McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ¹⁰Internal Medicine and Rheumatology, Reference Center for Osteoporosis, Rheumatology & Dermatology. Pontificia Javeriana University, Calí, Colombia
Background/Purpose: Sustained minimal disease activity (MDA) is only achieved by a small portion of PsA patients (pts). Levels of disease activity consistent with MDA may…
Abstract Number: 0110 • ACR Convergence 2022
Does Access Reduce Excess Use? Lupus Outcomes in Two Distinct Socioeconomic Groups Seen by University Rheumatologists
Alissa Chandler¹, Rodney Tehrani¹ and Varun Bhalla², ¹Loyola University Medical Center, Maywood, IL, ²Loyola University Medical cneter, Chicago, IL
Background/Purpose: SLE is a multi-organ chronic autoimmune disease, which requires chronic medication use and close follow up with a rheumatologist. Poor disease control can lead…
Abstract Number: 0364 • ACR Convergence 2022
Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part A)
Richard Furie¹, Ronald van Vollenhoven², Victoria Werth³, Kenneth Kalunian⁴, Sandra Navarra⁵, Juanita Romero-Diaz⁶, Ting Wang⁷, Cristina Musselli⁷, Catherine Barbey⁸ and Nathalie Franchimont⁷, ¹Northwell Health, Great Neck, NY, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴University of California San Diego, La Jolla, CA, ⁵University of Santo Tomas, Manila, Philippines, ⁶Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁷Biogen, Cambridge, MA, ⁸Biogen, Baar, Switzerland
Background/Purpose: SLE is a heterogeneous illness that often manifests with skin and/or joint diseases.1 BIIB059 is a humanized monoclonal antibody that binds to BDCA2, a…
Abstract Number: 0761 • ACR Convergence 2022
Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group
Nilasha Ghosh¹, Nina Couette², Wouter van Binsbergen³, Sophia Weinmann⁴, Bridget Jivanelli¹, Beverley Shea⁵, Anne Bass⁶, Karolina Benesova⁷, Clifton O. Bingham III⁸, Cassandra Calabrese⁹, Laura C. Cappelli¹⁰, Karmela Kim Chan¹, Ernest Choy¹¹, Dimitrios Daoussis¹², Susan Goodman¹, Marie Hudson¹³, Shahin Jamal¹⁴, Jan Leipe¹⁵, Maria A. Lopez-Olivo¹⁶, Maria Suarez-Almazor¹⁷, Conny van der Laken¹⁸, Alexa Meara¹⁹, David Liew²⁰ and Marie Kostine²¹, ¹Hospital for Special Surgery, New York, NY, ²Department of Internal Medicine. Division of Rheumatology & Immunology, The Ohio State University, Columbus, OH, ³Amsterdam Rheumatology and Immunology Center, Department of Rheumatology & Clinical Immunology, Amsterdam University Medical Center location DBL, Amsterdam, Netherlands, ⁴Department of Rheumatology & Immunology, Duke University, Durham, NC, ⁵School of Epidemiology and Public Health, University of Ottawa, Ottawa, ⁶Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁷University Hospital Heidelberg, Heidelberg, Germany, ⁸Johns Hopkins University, Baltimore, MD, ⁹Cleveland Clinic Foundation, Cleveland Heights, OH, ¹⁰Johns Hopkins School of Medicine, Baltimore, MD, ¹¹Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ¹²Department of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece, ¹³McGill University, Montréal, QC, Canada, ¹⁴University of British Columbia, Vancouver, BC, Canada, ¹⁵Division of Rheumatology, Department of Medicine V, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany, ¹⁶The University of Texas, MD Anderson Cancer Center, Houston, TX, ¹⁷MD Anderson Cancer Center, Houston, TX, ¹⁸Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ¹⁹The Ohio State University Wexner Medical Center, Columbus, OH, ²⁰Austin Health, Heidelberg, Australia, ²¹Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA)…
Abstract Number: 1217 • ACR Convergence 2022
The Problem of Pain in Rheumatology: Clinical Profiles Associated with Concomitant Diagnoses with Chronic Overlapping Pain Conditions
Titilola Falasinnu¹, Yashaar Chaichian² and Julia Simard³, ¹Stanford School of Medicine, Stanford, CA, ²Stanford University, Stanford, CA, ³Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: The chronification of pain is heterogeneous in rheumatology. Chronic overlapping pain conditions (COPCs) such as fibromyalgia, endometriosis, migraine, and back pain may co-occur with…
Abstract Number: 1482 • ACR Convergence 2022
Latent Tuberculosis Infection and Its Associations with Clinical and Serological Parameters in Systemic Lupus Erythematosus
Gayathri MS¹, Chengappa Kavadichanda², Aishwarya Gopal³, Devender Bairwa⁴, Molly Thabah¹, Sonali Sarkar⁵ and Prakash Babu Narasimhan¹, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ²JIPMER, Pondicherry, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Latent tuberculosis infection (L-TB) detected by mycobacterium tuberculosis (TB) IFN-γ release assay (TB-IGRA), besides identifying latent infection may predict the disease status in SLE.…
Abstract Number: 1872 • ACR Convergence 2022
Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study
Fahidah Alenzi¹, Shirish Sangle² and Sanna Giovanni², ¹Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, ²Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Background/Purpose: Idiopathic inflammatory myositis (IIM) includes a spectrum of a rare autoimmune disease characterized by proximal muscle weakness, variable skin manifestation and extra muscular manifestations.…
Abstract Number: 2110 • ACR Convergence 2022
Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Laure Gossec¹, Mohamed Sharaf², Elke Theander³, Marlies Neuhold⁴, Paul Bergmans⁵, May Shawi⁶, Michelle Perate⁷, Christine Contré⁸ and Laura Coates⁹, ¹Sorbonne Université, Paris, France, ²Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ³Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Formerly at Janssen, Breda, Netherlands, ⁶Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…
Abstract Number: 0155 • ACR Convergence 2022
Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis
Sarvar Nazir¹, Kelly Rouster-Stevens², Julie Fuller³, Hanna Kim⁴, Vy Do⁵, Rita Volochayev⁶, Anna Jansen⁶, Nastaran Bayat⁷, Lisa G Rider⁸ and Adam Schiffenbauer⁶, ¹National Institutes of Health, Charlotte, NC, ²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³UT Southwestern, Frisco, TX, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁵UT Austin Dell Medical School, Austin, TX, ⁶National Institutes of Health, Bethesda, MD, ⁷Social & Scientific Systems, Inc., a DLH Holdings Corp (DLH) company, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis is a complication of the idiopathic inflammatory myopathies (IIM) in which calcium salts are deposited in and around soft tissue, which can impact…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].